I suspect--but don't know--that it reflects the higher trial expenses that reflect the high number of patient screens necessary to find patients who fit SA criteria. I'd be curious as to what the agreement with Quintiles is regarding this kind of added cost--which can be at least partly attributed to a disconnect between what Quintiles promised in enrollment, and what they delivered. If nothing else, Quintiles would (I suspect) as a result be flexible on payment timeliness, allowing the 'fumes' to sustain Cortex longer than the numbers would seem to indicate.
NeuroInvestment
Market Data 
Markets 
AI
